
WHAT IS CLAIMED IS:

1. A compound having formula (**I**):













(**I**)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

R^1 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl, and optionally substituted heteroaryl;

R^2 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl, and optionally substituted heteroaryl;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted heteroaryl, , , , , , , , , , , and ;

n is 1, 2, or 3;


L^1 is, independently, -$[C(R^{4a}R^{4b})]_m$-;

m is 1 or 2;

R^{4a} and R^{4b} are, at each occurrence, each independently selected from a group consisting of hydrogen and methyl;

R^{4a} and R^{4b} are taken together with the atom to which they are bound to form a cyclopropyl ring; and x, at each occurrence, independently is 0 or 1.


2. The compound according to claim 1 having formula (**1e**)



(Ie)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


3. The compound according to claim 1 having formula (**1f**)



(If)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


4. The compound according to claim 1 having formula (**1g**)



(Ig)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


5. The compound according to claim 1 having formula (**1h**)



(Ih)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


6. A compound having formula (**Ia**):



(Ia)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


7. A compound having formula (**Ib**):



(Ib)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


8. A compound having formula (**Ic**):



(Ic)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


9. A compound having formula (**Id**):



(Id)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

10. A compound having formula (**II**):



(II)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

R^8 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl, and optionally substituted heteroaryl;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1-C_6 linear alkyl, and optionally substituted C_1-C_6 branched alkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, and optionally substituted C_3-C_7 cycloalkyl;

X^1 is selected from the group consisting of CH and nitrogen;

X^2 is selected from the group consisting of, sulfur, oxygen, and NH;

L^2 is, independently, $-[C(R^{11a}R^{11b})]_q-$;


q is 1 or 2;

R^{11a} and R^{11b} are, at each occurrence, each independently selected from the group consisting of hydrogen and methyl;

R^{11a} and R^{11b} are taken together with the atom to which they are bound to form a cyclopropyl ring;

and y is 0 or 1.


11. The compound according to claim 10 having formula (**IIa**):



(**IIa**)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


12. The compound according to claim 10 having formula (**IIb**):



(**IIb**)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


13. The compound according to claim 10 having formula (**III**):



(**III**)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.


14. A compound having formula (**IV**):



(**IV**)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

15. A compound having formula (**V**):



(V)

Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

16. A compound selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl)acetamide;

N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;

tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)methyl) piperidine-1-carboxylate;
tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl) phenyl)phenylsulfonamido)acetamido) ethyl)carbamate;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;
N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((1-methylpiperidin-4-yl)methyl)acetamide;
4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;
2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;
N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;
N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-chloro-5-trifluoromethyl-phenyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-pyridin-4-ylmethyl-benzamide;

1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;
1-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;
or a pharmaceutically acceptable form thereof.

17. A composition comprising an effective amount of at least one compound according to claim 1 and at least one pharmaceutically acceptable excipient.
18. A composition comprising an effective amount of at least one compound according to claim 6 and at least one pharmaceutically acceptable excipient.
19. A composition comprising an effective amount of at least one compound according to claim 7 and at least one pharmaceutically acceptable excipient.
20. A composition comprising an effective amount of at least one compound according to claim 8 and at least one pharmaceutically acceptable excipient.
21. A composition comprising an effective amount of at least one compound according to claim 9 and at least one pharmaceutically acceptable excipient.
22. A composition comprising an effective amount of at least one compound according to claim 10 and at least one pharmaceutically acceptable excipient.
23. A composition comprising an effective amount of at least one compound according to claim 13 and at least one pharmaceutically acceptable excipient.
24. A composition comprising an effective amount of at least one compound according to claim 14 and at least one pharmaceutically acceptable excipient.
25. A composition comprising an effective amount of at least one compound according to claim 15 and at least one pharmaceutically acceptable excipient.
26. A composition comprising at least one pharmaceutically acceptable excipient and an effective amount of at least one compound selected from the group consisting of:
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)butanamide;
2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl)acetamide;
N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;
tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)methyl) piperidine-1-carboxylate;
tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl) phenyl)phenylsulfonamido)acetamido) ethyl)carbamate;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;
N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((1-methylpiperidin-4-yl)methyl)acetamide;
4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;

2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;
N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;
N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-(2-chloro-5-trifluoromethyl-phenyl)-benzamide;
4-(Benzyl-methyl-sulfamoyl)-N-pyridin-4-ylmethyl-benzamide;
1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;
1-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;
or a pharmaceutically acceptable form thereof.

27. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.
28. The method of claim 27, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.

29. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 6 to treat the disease.
30. The method of claim 29, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
31. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 7 to treat the disease.
32. The method of claim 31, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
33. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 8 to treat the disease.
34. The method of claim 23, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
35. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 9 to treat the disease.
36. The method of claim 35, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
37. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 10 to treat the disease.
38. The method of claim 37, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
39. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 13 to treat the disease.
40. The method of claim 39, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.

41. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 14 to treat the disease.
42. The method of claim 41, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
43. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject an effective amount of at least one compound according to the claim 15 to treat the disease.
44. The method of claim 43, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
45. A method of treating a disease associated with covalently closed circular DNA formation, such as hepatitis B, said method comprising administering to a subject at least one pharmaceutically acceptable excipient and an effective amount of at least one compound selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl)acetamide;
N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;
tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)methyl) piperidine-1-carboxylate;
tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl) phenyl)phenylsulfonamido)acetamido) ethyl)carbamate;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;
N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;
2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((1-methylpiperidin-4-yl)methyl)acetamide;
4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;
2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;
2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;

N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-1H-indol-5-yl)-benzamide;

N-Benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-(2-chloro-5-trifluoromethyl-phenyl)-benzamide;

4-(Benzyl-methyl-sulfamoyl)-N-pyridin-4-ylmethyl-benzamide;


1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

1-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;

or a pharmaceutically acceptable form thereof.

CLAIMS

1. A compound having formula **(Ia)**:




(Ia)

or hydrates, solvates, or pharmaceutically acceptable salts thereof, wherein:

R^1 is 2,5-substituted phenyl, wherein the substituents at the 2-position and 5-position of the phenyl are independently selected from the group consisting of halo and trifluoromethyl;

R^2 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl,



n is 1, 2, or 3;


L^1 is, independently, -$[C(R^{4a}R^{4b})]_m$-;

m is 1 or 2;

at each occurrence R^{4a} and R^{4b} are each independently selected from a group consisting of hydrogen and methyl; or R^{4a} and R^{4b} are taken together with the carbon atom to which they are bound to form a cyclopropyl ring; and

at each occurrence x is independently 0 or 1.


2. The compound of claim 1 having formula **(Ie)**:



(Ie)

or hydrates, solvates, or pharmaceutically acceptable salts thereof.


3. The compound of claim 1 having formula **(If)**:



(If)

or hydrates, solvates, or pharmaceutically acceptable salts thereof.


4. The compound of claim 1 having formula **(Ig)**:



(Ig)

or hydrates, solvates, or pharmaceutically acceptable salts thereof.


5. The compound of claim 1 having formula **(Ih)**:



(**Ih**)

or hydrates, solvates, or pharmaceutically acceptable salts thereof.


6. The compound of claim 1 having formula (**I**):



(**I**)

or hydrates, solvates, or pharmaceutically acceptable salts thereof.

7. A compound having formula **(Ib):**



(**Ib**)


or hydrates, solvates, or pharmaceutically acceptable salts thereof, wherein:

R^1 is 2,5-substituted phenyl, wherein the substituents at the 2-position and 5-position of the phenyl are independently selected from the group consisting of halo and trifluoromethyl;

R^2 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl; and

n is 1, 2, or 3.

8. A compound having formula **(Ic)**:




(Ic)

or hydrates, solvates, or pharmaceutically acceptable salts thereof, wherein:

R^2 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl,




L^1 is, independently, -$[C(R^{4a}R^{4b})]_m$-;

m is 1 or 2;

at each occurrence R^{4a} and R^{4b} are each independently selected from a group consisting of hydrogen and methyl; or R^{4a} and R^{4b} are taken together with the carbon atom to which they are bound to form a cyclopropyl ring; and

at each occurrence x is independently 0 or 1.

9. A compound having formula **(Id)**:




(Id)

or hydrates, solvates, or pharmaceutically acceptable salts thereof, wherein:

R^2 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted C_1-C_6 linear alkyl, optionally substituted C_1-C_6 branched alkyl, optionally substituted C_3-C_7 cycloalkyl,



L^1 is, independently, -$[C(R^{4a}R^{4b})]_m$-;

m is 1 or 2;

at each occurrence R^{4a} and R^{4b} are each independently selected from a group consisting of hydrogen and methyl; or R^{4a} and R^{4b} are taken together with the carbon atom to which they are bound to form a cyclopropyl ring; and

at each occurrence x is independently 0 or 1.

10. The compound of any of claims 1-9, which is selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-

acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl) acetamide;

N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;

tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido) methyl)piperidine-1-carboxylate;

tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)ethyl) carbamate;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl)

acetamide;

N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((l-methylpiperidin-4-yl) methyl) acetamide;

4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;

2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

l-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;

and a pharmaceutically acceptable form thereof.

11. A pharmaceutical composition comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable excipient.

12. A pharmaceutical composition comprising at least one compound according to claim 6 and at least one pharmaceutically acceptable excipient.

13. A pharmaceutical composition comprising at least one compound according to claim 7 and at least one pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising at least one compound according to claim 8 and at least one pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising at least one compound according to claim 9 and at least one pharmaceutically acceptable excipient.

16. A pharmaceutically acceptable composition comprising at least one pharmaceutically acceptable excipient and at least one compound of any of claims 1-9, which is selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-yl-methyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl)

acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl) acetamide;

N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3 ,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;

tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido) methyl)piperidine-1-carboxylate;

tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)ethyl) carbamate;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;

N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((l-methylpiperidin-4-yl) methyl) acetamide;

4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;

2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

l-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;

and a pharmaceutically acceptable form thereof.

17. An effective amount of at least one compound according to the claim 1, for use in the treatment of hepatitis B.

18. The at least one compound of claim 17, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

19. An effective amount of at least one compound according to the claim 6, for use in the treatment of hepatitis B.

20. The at least one compound of claim 19, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

21. An effective amount of at least one compound according to the claim 7 for use in the treatment of hepatitis B.

22. The at least one compound of claim 21, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

23. An effective amount of at least one compound according to the claim 8 for use in the treatment of hepatitis B.

24. The at least one compound of claim 23, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

25. An effective amount of at least one compound according to the claim 9 for use in

the treatment of hepatitis B.

26. The at least one compound of claim 25, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

27. An effective amount of at least one compound of any of claims 1-9, which is selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-yl-methyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl) acetamide;

N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3 ,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;

tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido) methyl)piperidine-1-carboxylate;

tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)ethyl) carbamate;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;

N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((l-methylpiperidin-4-yl) methyl) acetamide;

4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;

2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;


2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;


l-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;

and a pharmaceutically acceptable form thereof for use in the treatment of hepatitis B.

28. The compound of claim 1, wherein R^3 is selected from the group consisting of:



29. The compound of claim 1, wherein the optionally substituted phenyl in R^3 is



30. The compound of claim 1, wherein R^1 is selected from the group consisting of 2-chloro-5-trifluoromethyl-phenyl, 2-fluoro-5-chloro-phenyl, 2-bromo-5-trifluoromethyl-phenyl and 2-fluoro-5-trifluoromethyl-phenyl.

31. The compound of claim 1, wherein R^2 is selected from the group consisting of phenyl, 4-methyl-phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methoxy-phenyl, 4-trifluoro-methyl-phenyl and 2-chloro-4-trifluoromethyl-phenyl.

32. The use of an effective amount of at least one compound according to the claim 1 in the manufacture of a medicament for the treatment of hepatitis B.

33. The use of claim 32, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

34. The use of an effective amount of at least one compound according to the claim 6 in the manufacture of a medicament for the treatment of hepatitis B.

35. The use of claim 34, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

36. The use of an effective amount of at least one compound according to the claim 7 in the manufacture of a medicament for the treatment of hepatitis B.

37. The use of claim 36, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

38. The use of an effective amount of at least one compound according to the claim 8 in the manufacture of a medicament for the treatment of hepatitis B.

39. The use of claim 38, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

40. The use of an effective amount of at least one compound according to the claim 9 in the manufacture of a medicament for the treatment of hepatitis B.

41. The use of claim 40, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

42. The use of an effective amount of at least one compound of at least one compound of any of claims 1-9, which is selected from the group consisting of:

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[(2-Chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino]-N-pyridin-4-yl-methyl-acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) propanamide;

4-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) butanamide;

2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl acetamide;

2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(2-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)-4-(trifluoromethyl) phenylsulfonamido)-N-(pyridin-4-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyridin-3-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-5-ylmethyl) acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenyl sulfonamido)-N-(pyrimidin-4-ylmethyl) acetamide;

N-(2-chloro-5-(trifluoromethyl)phenyl)-N-(2-(3 ,4-dihydro-2,6-naphthyridin-2(1H)-yl)-2-oxoethyl)benzenesulfonamide;

tert-butyl 4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido) methyl)piperidine-1-carboxylate;

tert-butyl (2-(2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamido)ethyl) carbamate;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(piperidin-4-ylmethyl) acetamide;

N-(2-aminoethyl)-2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)acetamide;

2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((l-methylpiperidin-4-yl) methyl) acetamide;

4-((2-(N-(2-chloro-5-(trifluoromethyl)phenyl) phenylsulfonamido)acetamido)methyl)-1,1-dimethylpiperidin-1-ium chloride;

2-[Benzenesulfonyl-(2-bromo-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-propionamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-1-yl)-benzyl]-acetamide;

1-Benzenesulfonyl-pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

l-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide;

and a pharmaceutically acceptable form thereof in the manufacture of a medicament for the treatment of hepatitis B.